Preliminary Findings Associate Hippocampal ¹H-MR Spectroscopic Metabolite Concentrations with Psychotic and Manic Symptoms in Patients with Schizophrenia

References

1. 1.↵
   American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed, DSM-5. American Psychiatric Association; 2013
2. 2.↵
   1. Tamminga CA,
   2. Pearlson GD,
   3. Stan AD, et al

   . Strategies for advancing disease definition using biomarkers and genetics: the bipolar and schizophrenia network for intermediate phenotypes. Biol Psychiatry Cogn Neurosci Neuroimaging 2017;2:20–27 doi:10.1016/j.bpsc.2016.07.005 pmid:29560884

   CrossRefPubMed
3. 3.↵
   1. Nenadic I,
   2. Gaser C,
   3. Sauer H

   . Heterogeneity of brain structural variation and the structural imaging endophenotypes in schizophrenia. Neuropsychobiology 2012;66:44–49 doi:10.1159/000338547 pmid:22797276

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Schobel SA,
   2. Chaudhury NH,
   3. Khan UA, et al

   . Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron 2013;78:81–93 doi:10.1016/j.neuron.2013.02.011 pmid:23583108

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Talati P,
   2. Rane S,
   3. Skinner J, et al

   . Increased hippocampal blood volume and normal blood flow in schizophrenia. Psychiatry Res 2015;232:219–25 doi:10.1016/j.pscychresns.2015.03.007 pmid:25896442

   CrossRefPubMed
6. 6.↵
   1. Balu DT,
   2. Lucki I

   . Adult hippocampal neurogenesis: regulation, functional implications, and contribution to disease pathology. Neurosci Biobehav Rev 2009;33:232–52 doi:10.1016/j.neubiorev.2008.08.007 pmid:18786562

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Rametti G,
   2. Junque C,
   3. Vendrell P, et al

   . Hippocampal underactivation in an fMRI study of word and face memory recognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2009;259:203–11 doi:10.1007/s00406-008-0852-5 pmid:19224116

   CrossRefPubMed
8. 8.↵
   1. Watson DR,
   2. Bai F,
   3. Barrett SL, et al

   . Structural changes in the hippocampus and amygdala at first episode of psychosis. Brain Imaging Behav 2012;6:49–60 doi:10.1007/s11682-011-9141-4 pmid:22045236

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Heckers S,
   2. Konradi C

   . Hippocampal pathology in schizophrenia. Curr Top Behav Neurosci 2010;4:529–53 doi:10.1007/7854_2010_43 pmid:21312412

   CrossRefPubMed
10. 10.↵
    1. Haukvik UK,
    2. Hartberg CB,
    3. Agartz I

    . Schizophrenia: what does structural MRI show [in Norwegian]? Tidsskr Nor Laegeforen 2013;133:850–53 doi:10.4045/tidsskr.12.1084 pmid:23612107

    CrossRefPubMed
11. 11.↵
    1. Bustillo JR

    . Use of proton magnetic resonance spectroscopy in the treatment of psychiatric disorders: a critical update. Dialogues Clin Neurosci 2013;15:329–37 pmid:24174904

    CrossRefPubMed
12. 12.↵
    1. Mountford CE,
    2. Stanwell P,
    3. Lin A, et al

    . Neurospectroscopy: the past, present and future. Chem Rev 2010;110:3060–86 doi:10.1021/cr900250y pmid:20387805

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Zhu H,
    2. Barker PB

    . MR spectroscopy and spectroscopic imaging of the brain. Methods Mol Biol 2011;711:203–26 doi:10.1007/978-1-61737-992-5_9 pmid:21279603

    CrossRefPubMed
14. 14.↵
    1. Iwata Y,
    2. Nakajima S,
    3. Plitman E, et al

    . Neurometabolite levels in antipsychotic-naive/free patients with schizophrenia: a systematic review and meta-analysis of (1)H-MRS studies. Prog Neuropsychopharmacol Biol Psychiatry 2018;86:340–52 doi:10.1016/j.pnpbp.2018.03.016 pmid:29580804

    CrossRefPubMed
15. 15.↵
    1. Port JD,
    2. Agarwal N

    . MR spectroscopy in schizophrenia. J Magn Reson Imaging 2011;34:1251–61 doi:10.1002/jmri.22787 pmid:22102558

    CrossRefPubMed
16. 16.↵
    1. Meyer EJ,
    2. Kirov II,
    3. Tal A, et al

    . Metabolic abnormalities in the hippocampus of patients with schizophrenia: a 3D multivoxel MR spectroscopic imaging study at 3T. AJNR Am J Neuroradiol 2016;37:2273–79 doi:10.3174/ajnr.A4886 pmid:27444940

    Abstract/FREE Full Text
17. 17.↵
    1. Tognin S,
    2. van Hell HH,
    3. Merritt K, et al

    ; PSYSCAN Consortium. Towards precision medicine in psychosis: benefits and challenges of multimodal multicenter studies-PSYSCAN: translating neuroimaging findings from research into clinical practice. Schizophr Bull 2020;26;46:432–41 doi:10.1093/schbul/sbz067 pmid:31424555

    CrossRefPubMed
18. 18.↵
    1. Kay SR,
    2. Fiszbein A,
    3. Opler LA

    . The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–76 doi:10.1093/schbul/13.2.261 pmid:3616518

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Hamilton M

    . Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278–96 doi:10.1111/j.2044-8260.1967.tb00530.x pmid:6080235

    CrossRefPubMed
20. 20.↵
    1. Young RC,
    2. Biggs JT,
    3. Ziegler VE, et al

    . A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429–35 doi:10.1192/bjp.133.5.429 pmid:728692

    Abstract/FREE Full Text
21. 21.↵
    1. Goelman G,
    2. Liu S,
    3. Hess D, et al

    . Optimizing the efficiency of high-field multivoxel spectroscopic imaging by multiplexing in space and time. Magn Reson Med 2006;56:34–40 doi:10.1002/mrm.20942 pmid:16767711

    CrossRefPubMed
22. 22.↵
    1. Soher BJ,
    2. Young K,
    3. Govindaraju V, et al

    . Automated spectral analysis III: application to in vivo proton MR spectroscopy and spectroscopic imaging. Magn Reson Med 1998;40:822–31 doi:10.1002/mrm.1910400607 pmid:9840826

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Boccardi M,
    2. Bocchetta M,
    3. Apostolova LG

    , et al; EADC-ADNI Working Group on the Harmonized Protocol for Manual Hippocampal Segmentation. Delphi definition of the EADC-ADNI Harmonized Protocol for hippocampal segmentation on magnetic resonance. Alzheimers Dement 2015;11:126–38 doi:10.1016/j.jalz.2014.02.009 pmid:25130658

    CrossRefPubMed
24. 24.↵
    1. Frisoni GB,
    2. Jack CR Jr.,
    3. Bocchetta M, et al

    ; EADC-ADNI Working Group on The Harmonized Protocol for Manual Hippocampal Volumetry and for the Alzheimer's Disease Neuroimaging Initiative. The EADC-ADNI harmonized protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity. Alzheimers Dement 2015;11:111–25 doi:10.1016/j.jalz.2014.05.1756 pmid:25267715

    CrossRefPubMed
25. 25.↵
    1. Tal A,
    2. Kirov I,
    3. Grossman RI, et al

    . The role of gray and white matter segmentation in quantitative proton MR spectroscopic imaging. NMR Biomed 2012;25:1392–1400 doi:10.1002/nbm.2812 pmid:22714729

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Fusar-Poli P,
    2. McGorry PD,
    3. Kane JM

    . Improving outcomes of first-episode psychosis: an overview. World Psychiatry 2017;16:251–65 doi:10.1002/wps.20446 pmid:28941089

    CrossRefPubMed
27. 27.↵
    1. Allen P,
    2. Moore H,
    3. Corcoran CM, et al

    . Emerging temporal lobe dysfunction in people at clinical high risk for psychosis. Front Psychiatry 2019;10:298 doi:10.3389/fpsyt.2019.00298 pmid:31133894

    CrossRefPubMed
28. 28.↵
    1. Tibbo P,
    2. Hanstock C,
    3. Valiakalayil A, et al

    . 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am J Psychiatry 2004;161:1116–18 doi:10.1176/appi.ajp.161.6.1116 pmid:15169703

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Nelson JA,
    2. Dou H,
    3. Ellison B, et al

    . Coregistration of quantitative proton magnetic resonance spectroscopic imaging with neuropathological and neurophysiological analyses defines the extent of neuronal impairments in murine human immunodeficiency virus type-1 encephalitis. J Neurosci Res 2005;80:562–75 doi:10.1002/jnr.20466 pmid:15825192

    CrossRefPubMed
30. 30.↵
    1. Stedehouder J,
    2. Couey JJ,
    3. Brizee D, et al

    . Fast-spiking parvalbumin interneurons are frequently myelinated in the cerebral cortex of mice and humans. Cereb Cortex 2017;27:5001–13 doi:10.1093/cercor/bhx203 pmid:28922832

    CrossRefPubMed
31. 31.↵
    1. Lisman JE,
    2. Coyle JT,
    3. Green RW, et al

    . Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 2008;31:234–42 doi:10.1016/j.tins.2008.02.005 pmid:18395805

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Hakak Y,
    2. Walker JR,
    3. Li C, et al

    . Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A 2001;98:4746–51 doi:10.1073/pnas.081071198 pmid:11296301

    Abstract/FREE Full Text
33. 33.↵
    1. Small SA,
    2. Schobel SA,
    3. Buxton RB, et al

    . A pathophysiological framework of hippocampal dysfunction in ageing and disease. Nat Rev Neurosci 2011;12:585–601 doi:10.1038/nrn3085 pmid:21897434

    CrossRefPubMed
34. 34.↵
    1. Harrisberger F,
    2. Smieskova R,
    3. Vogler C, et al

    . Impact of polygenic schizophrenia-related risk and hippocampal volumes on the onset of psychosis. Transl Psychiatry 2016;6:e868 doi:10.1038/tp.2016.143 pmid:27505231

    CrossRefPubMed